BioNTech is the Marketing Authorisation Holder for BNT162b2 (Original) and BNT162b2 Bivalent (Original/Omicron BA.4/BA.5) in the US, EU, UK, Canada, and other countries.

Pfizer and BioNTech have been among the leaders in the race to bring a combined COVID-19 and influenza vaccine to market, but have stumbled in the final straight. The companies reported mixed ...

March 10, 2025 BioNTech guides for worse-than-expected 2025 revenue decline German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion ...

German biotech firm BioNTech reported a loss of €665.3 million ($721 million) in 2024, as demand for its COVID-19 vaccines fell, according to the company's financial results report on Monday.